Search

Displaying results 1031 - 1040 of 4539 in total
  1. Drug

    Trihexyphenidyl

    go.drugbank.com/drugs/DB00376
    ApprovedInvestigational

    [L31843] It has largely been replaced by drugs such as [levodopa].[L31843] Trihexyphenidyl was granted FDA approval on 13 May 1949.[L31768]

  2. Drug

    Empagliflozin

    go.drugbank.com/drugs/DB09038
    ApprovedInvestigational

    [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. … [L13688] The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for

  3. Drug

    Fluocinolone acetonide

    go.drugbank.com/drugs/DB00591
    ApprovedInvestigationalVet approved

    [T358] This type of device containing fluocinolone acetonide was developed by Taro Pharmaceuticals and approved by FDA in May 2016.[L4676]

  4. Drug

    Hexylcaine

    go.drugbank.com/drugs/DB00473
    ApprovedWithdrawn

    Hexylcaine has been discontinued in the US market.

  5. Drug

    Coral snake (micrurus fulvius) immune globulin antivenin (equine)

    go.drugbank.com/drugs/DB13883
    Approved

    North American Coral Snake Antivenin (Equine) is a horse-derived antivenin indicated for the treatment of envenomation caused by North American coral snake bites. … The antivenin is a refined, concentrated, and lyophilized preparation of serum globulins obtained by fractionating blood from healthy horses that have been immunized with eastern coral snake (Micrurus

  6. Drug

    Pralidoxime

    go.drugbank.com/drugs/DB00733
    ApprovedInvestigationalVet approved

    If given within 24 hours,after organophosphate exposure, pralidoxime reactivates the enzyme cholinesterase by cleaving the phosphate-ester bond formed between the organophosphate and acetylcholinesterase

  7. Drug

    Pemigatinib

    go.drugbank.com/drugs/DB15102
    ApprovedInvestigational

    growth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an FDA-approved test. … With increasing research on the pathogenesis of cholangiocarcinoma and potential therapeutic targets for anticancer drug treatment, recent studies show that up to 45% of patients with intrahepatic cholangiocarcinoma

  8. Drug

    Cytarabine

    go.drugbank.com/drugs/DB00987
    ApprovedInvestigational

    A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specif...

    International brands: Cytosar-UProducts: CYTOSAR-U
  9. Drug

    Tarlatamab

    go.drugbank.com/drugs/DB17256
    ApprovedInvestigational

    [L50743] Tarlatamab-dlle was approved by the FDA in May 2024 for use in patients who have failed previous round of platinum-based chemotherapy,[L50743,L50748] becoming the first DLL3-targeting bispecific

  10. Drug

    Cabozantinib

    go.drugbank.com/drugs/DB08875
    ApprovedInvestigational

    It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. … [L15123] In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019